DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22008/S-003, S-004, S-007, S-008

SUPPLEMENT APPROVAL

GlaxoSmithKline LLC
Attention: Jaisri Giridhar, PhD, DABT, RAC,
Manager, Global Regulatory Affairs
5 Moore Drive
PO Box 13398
Research Triangle Park, NC 27709-3398

Dear Dr. Giridhar:

Please refer to your Supplemental New Drug Applications (sNDAs), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for REQUIP XL Extended-Release Oral Tablets, 2mg, 3mg, 4mg, 6mg, 8mg, and 12mg:

S-003	submitted and received:	December 12, 2008
S-004	submitted and received:	May 1, 2009
S-007	submitted and received:	August 30, 2012
S-008	submitted and received:	June 18, 2013

We also refer to our approval letter dated August 28, 2014, which contained the following error: the labeling attached to the approval letter was that of Requip rather than Requip XL.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain August 28, 2014, the date of the original approval letter.

S-003

Supplement Type:	Prior Approval
Dated:	December 12, 2008
Received:	December 12, 2008
Amended:	April 13, 2012
Proposes:	Addition of information into the Full Prescribing Information regarding dosing recommendations for patients with end stage renal disease based on a pharmacokinetic study (Study RRL103628)

S-004

Supplement Type:	Prior Approval
Dated:	May 1, 2009
Received:	May 1, 2009
Amended:	April 13, 2012
Proposes:	Addition of information into the Full Prescribing Information and Patient Information regarding hypersensitivity reactions and melanoma

S-007

Supplement Type:	Prior Approval
Dated:	August 30, 2012
Received:	August 30, 2012
Proposes:	Addition of information into the Full Prescribing Information and Patient Information regarding the effect of gastrointestinal transit time on medication release

S-008

Supplement Type:	Prior Approval
Dated:	June 18, 2013
Received:	June 18, 2013
Amended:	June 21, 2013
Proposes:	Addition of information into the Full Prescribing Information and Patient Information regarding aggressive behavior, compulsive spending or buying, binge eating and compulsive eating based on postmarketing reports

We also note this approval includes the addition of results from your postmarketing commitment (PMC) study to evaluate whether ropinirole is a P-gp substrate and/or inducer for major CYP enzymes, for which a PMC Fulfilled letter was issued on June 10, 2014.

We remind you that the following postmarketing requirements listed in the June 13, 2008, approval letter are still open:

1. Conduct a fixed-dose, placebo-controlled, double-blinded study that examines multiple doses in early Parkinson's disease. The trial should identify a range of doses inclusive of the lowest effective dose and the lowest maximally effective therapeutic dose.
2. Conduct a fixed-dose, placebo-controlled, double-blinded study that examines multiple doses in late Parkinson's disease. The trial should identify a range of doses inclusive of the lowest effective dose and the lowest maximally effective therapeutic dose.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and the text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory

comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManuals Forms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/ UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tracy Peters, Senior Regulatory Project Manager, at (301) 796-2953.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
08/28/2014